<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017298</url>
  </required_header>
  <id_info>
    <org_study_id>CTX0020-004</org_study_id>
    <nct_id>NCT05017298</nct_id>
  </id_info>
  <brief_title>Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells</brief_title>
  <acronym>AdMSCs</acronym>
  <official_title>Clinical Study for Subjects With Coronavirus 2019 (COVID-19) Using Multiple Dose Intravenous Infusions of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltex Therapeutics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltex Therapeutics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a interventional new drug clinical trial for a Phase 2 randomized, double blind and&#xD;
      placebo control study using intravenous injection of autologous adipose stem cells (Celltex&#xD;
      AdMSCs) for subjects with severe COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The Phase 2 study is a randomized, double blind and placebo control study conducted initially in a single clinic facility.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of AdMSC injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study based on the rate of all AdMSC-associated adverse events (AEs) in all subjects.</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of treatment-related adverse events and severe adverse events during the study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety for AdMSCs based upon incidence of all AEs</measure>
    <time_frame>6 months</time_frame>
    <description>Grouped by Medical Dictionary for Regulatory Activities (MedDRA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mortality rate</measure>
    <time_frame>6 months</time_frame>
    <description>AdMSC treating group vs. control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recognized immune measurements evaluating patients' symptom changes and overall function</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate change of sequential organ failure assessment (SOFA) score as compare to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ functional tests including blood specific enzymes and proteins</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the efficacy of allogeneic AdMSCs for COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of weaning from mechanical ventilation</measure>
    <time_frame>6 months</time_frame>
    <description>Compared to control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of ICU monitoring</measure>
    <time_frame>6 months</time_frame>
    <description>Compared to control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of vasoactive agent's usage</measure>
    <time_frame>6 months</time_frame>
    <description>Compared to control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization (days)</measure>
    <time_frame>6 months</time_frame>
    <description>Compared to control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens (oropharyngeal swabs) using CDC standard method</measure>
    <time_frame>6 months</time_frame>
    <description>Compared to control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method</measure>
    <time_frame>6 months</time_frame>
    <description>Compared to control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive</measure>
    <time_frame>6 months</time_frame>
    <description>Compared to control group</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality rate down to 0%</measure>
    <time_frame>6 months</time_frame>
    <description>For severe and critical cases</description>
  </other_outcome>
  <other_outcome>
    <measure>Achieve at least 30% more proportion of severe patients in AdMSC study group without developing organ failure or recovery from previous organ failure</measure>
    <time_frame>6 months</time_frame>
    <description>Compared to control group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject receives three separate doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion on day 0 , 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose-derived stem cells</intervention_name>
    <description>Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>Celltex-AdMSCs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age above 18 years.&#xD;
&#xD;
          -  Male and female&#xD;
&#xD;
          -  Must understand and voluntarily sign an Informed Consent for study participation&#xD;
             obtained prior to undergoing any study-specific procedures&#xD;
&#xD;
          -  Diagnosed as COVID-19 based upon SARS-CoV-2 RT-PCR test positive&#xD;
&#xD;
          -  Clinical diagnosis meets severe and/or critical parameters&#xD;
&#xD;
          -  Male participants must be willing to ensure their partners do not become pregnant&#xD;
             either by practicing abstinence or the use of condoms during sexual activity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical study (with use of another Investigational Medical&#xD;
             Product) within 3 months prior to study treatment start&#xD;
&#xD;
          -  Unwillingness or inability to comply with study procedures&#xD;
&#xD;
          -  Patients with serious basic diseases that affect survival, including blood diseases,&#xD;
             cachexia, active bleeding, severe malnutrition, etc.&#xD;
&#xD;
          -  Clinically active malignant disease&#xD;
&#xD;
          -  Subjects who are receiving ECMO and CRRT currently&#xD;
&#xD;
          -  History of known pulmonary embolism or known secondary anti-phospholipid syndrome&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any components used to culture the AdMSCs, e.g.&#xD;
             BSA and sulfur containing products (e.g., DMSO)&#xD;
&#xD;
          -  Known or suspected allergic to diphenhydramine.&#xD;
&#xD;
          -  Major trauma or surgery within 14 days of study treatment start&#xD;
&#xD;
          -  Mental condition rendering the subject (or the subject's legally acceptable&#xD;
             representative[s]) unable to understand the nature, scope and possible consequences of&#xD;
             the study&#xD;
&#xD;
          -  Alcohol, drug, or medication abuse within one year prior to study treatment start&#xD;
&#xD;
          -  Any condition that, in the Investigator's opinion, is likely to interfere with&#xD;
             evaluation of the AdMSC therapy or satisfactory conduct of the study&#xD;
&#xD;
          -  Irreversible severe end organ failure, such as heart failure/attack, stroke, liver and&#xD;
             renal failure due to other disease conditions&#xD;
&#xD;
          -  Patients or family history with hypercoagulable status, such as protein C/protein S&#xD;
             deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.&#xD;
&#xD;
          -  History of long-term use of immunosuppressive agents&#xD;
&#xD;
          -  Organ transplants in the past 6 months&#xD;
&#xD;
          -  Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth&#xD;
             control during participation in the study duration, unless surgically sterilized or&#xD;
             postmenopausal during the study.&#xD;
&#xD;
          -  Patients with previous pulmonary obstructive pneumonia, severe pulmonary interstitial&#xD;
             fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia&#xD;
             or bacterial pneumonia before COVID-19 infection. The pulmonary imaging revealed the&#xD;
             interstitial damage of lungs before the COVID-19 confirmed.&#xD;
&#xD;
          -  QT interval shows greater than 450 ms in males and 470 ms in females in the medical&#xD;
             histories or during screen EKG test.&#xD;
&#xD;
          -  Subjects are not medically unstable at time of infusion including but not limiting&#xD;
             unstable hypertension, pulse, oximetry, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek W Guillory, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Root Causes Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Young, Ph.D.</last_name>
    <phone>7135546823</phone>
    <email>jyoung@celltexbank.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sally McGahee</last_name>
    <phone>7135546847</phone>
    <email>smcgahee@celltexbank.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

